Enterprise Value
-18.39M
Cash
46.13M
Avg Qtr Burn
-9.127M
Short % of Float
0.13%
Insider Ownership
25.30%
Institutional Own.
3.98%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AXO-Lenti-PD (OXB-102) Details Parkinson's disease | Failed Discontinued | |
AXO-AAV-GM1 (GLB1) Details GM1 gangliosidosis, Lysosomal storage disorder | Failed Discontinued | |
AXO-AAV-GM2 Details Tay-Sachs/Sandhoff disease, GM2 gangliosidosis, Lysosomal storage disorder | Failed Discontinued |